Anbogen Therapeutics, Inc.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development 2024-02-01 00:00
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101 2022-09-13 22:00
1